VOOZH about

URL: https://en.wikipedia.org/wiki/Etripamil

⇱ Etripamil - Wikipedia

Jump to content
From Wikipedia, the free encyclopedia
Medication
Pharmaceutical compound
Etripamil
👁 Image
Clinical data
Trade namesCardamyst
Other namesMSP-2017
AHFS/Drugs.comcardamyst
License data
Routes of
administration		Intranasal
Drug classCalcium channel blocker
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC27H36N2O4
Molar mass452.595 g·mol−1
3D model (JSmol)
  • COC(=O)C1=CC(CCN(C)CCC[C@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)=CC=C1
  • InChI=1S/C27H36N2O4/c1-20(2)27(19-28,23-11-12-24(31-4)25(18-23)32-5)14-8-15-29(3)16-13-21-9-7-10-22(17-21)26(30)33-6/h7,9-12,17-18,20H,8,13-16H2,1-6H3/t27-/m0/s1
  • Key:VAZNEHLGJGSQEL-MHZLTWQESA-N
  • Key:JHOAIMAMBNLIMD-YCBFMBTMSA-N

Etripamil, sold under the brand name Cardamyst, is a medication used for the treatment of paroxysmal supraventricular tachycardia.[1] It is a calcium channel blocker.[1] It is used as a nasal spray.[1]

Etripamil was approved for medical use in the United States in December 2025.[2]

Medical uses

[edit]

Etripamil is indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia to sinus rhythm.[1][3][4]

Pharmacology

[edit]

Mechanism of action

[edit]

Etripamil is a voltage-dependent L-type calcium channel inhibitor.[3]

Society and culture

[edit]

Legal status

[edit]

Etripamil was approved for medical use in the United States in December 2025.[2]

Names

[edit]

Etripamil is the international nonproprietary name.[5]

Etripamil is sold under the brand name Cardamyst.[1]

References

[edit]
  1. ^ a b c d e f "Cardamyst (etripamil) nasal spray" (PDF). Milestone Pharmaceuticals USA, Inc. U.S. Food and Drug Administration. December 2025.
  2. ^ a b "Milestone Receives FDA Approval of Cardamyst (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)" (Press release). Milestone Pharmaceuticals. 13 December 2025. Retrieved 16 December 2025 – via GlobeNewswire News Room.
  3. ^ a b Calvert P, Gupta D (2024). "Intranasal etripamil for rapid treatment of paroxysmal supraventricular tachycardia". Future Cardiology. 20 (3): 163–170. doi:10.1080/14796678.2024.2342651. PMC 11216497. PMID 38717391.
  4. ^ Jha M, Song D, Kung A, Lo S, Sacher A, Ang SP, et al. (May 2025). "Efficacy and Safety of Intranasal Etripamil for Paroxysmal Supraventricular Tachycardia: Meta-Analysis of Randomized Controlled Trials". Journal of Clinical Medicine. 14 (11): 3720. doi:10.3390/jcm14113720. PMC 12155871. PMID 40507484.
  5. ^ World Health Organization (2016). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 75". WHO Drug Information. 30 (1). hdl:10665/331046.

External links

[edit]
  • Clinical trial number 03464019 for "Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT). (NODE-301)" at ClinicalTrials.gov
Calcium
VDCCsTooltip Voltage-dependent calcium channels
Blockers
Activators
Potassium
VGKCsTooltip Voltage-gated potassium channels
Blockers
Activators
IRKsTooltip Inwardly rectifying potassium channel
Blockers
Activators
KCaTooltip Calcium-activated potassium channel
Blockers
Activators
K2PsTooltip Tandem pore domain potassium channel
Blockers
Activators
Sodium
VGSCsTooltip Voltage-gated sodium channels
Blockers
Activators
ENaCTooltip Epithelial sodium channel
Blockers
Activators
ASICsTooltip Acid-sensing ion channel
Blockers
Chloride
CaCCsTooltip Calcium-activated chloride channel
Blockers
Activators
CFTRTooltip Cystic fibrosis transmembrane conductance regulator
Blockers
Activators
Unsorted
Blockers
Others
TRPsTooltip Transient receptor potential channels
LGICsTooltip Ligand gated ion channels
Categories:
Hidden categories: